Printed From:

In the Treat-to-Target study

An appropriate dose and proper titration helped many patients achieve glycemic targets.

Study Design

Data from a 24-week, multicenter, randomized, parallel, open-label trial of 756 overweight men and women compared the abilities and associated hypoglycemic effects of Lantus® added to prestudy OADs (n=367) vs NPH added to prestudy OADs (n=389) in insulin-naïve patients with type 2 diabetes and inadequate glycemic control (A1C >7.5%) on 1 or 2 oral agents (sulfonylureas, metformin, or thiazolidinediones) and treated to a target A1C ≤7.0%. Lantus® or NPH was administered once daily at bedtime. Primary endpoint was percentage of patients achieving A1C ≤7.0% without a single instance of symptomatic nocturnal hypoglycemia.

From Riddle1 and data on file.2

  • 1.7% mean A1C reduction at 24 weeks1,2
  • 58% of patients randomized to Lantus® achieved A1C ≤7%1

From Riddle1 and data on file.2

  • Titration is required to achieve FPG target1
  • Titration to appropriate fasting glucose target is necessary to help achieve glycemic goals
  • Lantus® dose at study end: 47 Units (range 10-144 Units)2

Safety Results1,2


  1. Riddle MC, Rosenstock J, Gerich J, on behalf of the Insulin Glargine 4002 Study Investigators. Diabetes Care. 2003;26:3080-3086.
  2. Data on file, Sanofi U.S. LLC.

Proven HbA1c control

See how Lantus® provides effective, improved glycemic control in diabetes patients.

Lantus® Prescribing Information. February 2015.

Once-daily dosing

Lantus® is a once-daily, long-acting insulin.**

**Lantus® Prescribing Information. February 2015.

Demonstrated long-term CV safety

Lantus® is a basal insulin with demonstrated long-term CV safety data††

††Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure. No difference was observed between Lantus® and standard of care in overall incidence of CV death, nonfatal MI, or nonfatal stroke. No difference was observed between treatment groups for death of any cause.